Cancer: antitumor effects of octreotide LAR, a somatostatin analog (Q43119401)

14 November 2017

title

Cancer: antitumor effects of octreotide LAR, a somatostatin analog (English)

1 reference

14 November 2017

Kjell Oberg

1

1 reference

14 November 2017

publication date

1 April 2010

1 reference

Nature Reviews Endocrinology

14 November 2017

published in

1 reference

14 November 2017

volume

6

1 reference

14 November 2017

issue

4

1 reference

14 November 2017

page(s)

188-189

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Neuroendocrine tumors. Biotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Rationale for the use of somatostatin analogs as antitumor agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Complete histological regression of metastatic carcinoid tumour after treatment with octreotide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.3

Carcinoid tumors and syndrome

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20336162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2010.3

1 reference

14 November 2017

1 reference